Short answer
SUPERNUS PHARMACEUTICALS, INC. (SUPN) filed an 8-K current report with the SEC on October 26, 2026 reporting Item 1.02 (Termination of a Material Definitive Agreement). UBS Credit Line terminated October 20, 2026 ahead of the Indivior business combination closing.
SUPERNUS PHARMACEUTICALS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.02 · Termination of a Material Definitive Agreement
- UBS Credit Line terminated October 20, 2026 ahead of the Indivior business combination closing
- No advances, letters of credit, or other borrowings outstanding at termination
- No early termination penalties, eliminating potential transaction-related costs
- UBS security interests released from the pledged securities collateral account
- Replacement senior secured credit facility expected at merger closing, reshaping combined-company financing
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other SUPERNUS PHARMACEUTICALS, INC. 8-K filings
Get the next SUPN 8-K as it lands
Follow SUPN for push alerts, or ask the research agent what this filing means.